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Purpose of the study
The OK04 clinical trial has shown, at 96 weeks, that lopi-
navir/ritonavir (LPV/r) monotherapy (MT) with re-intro-
duction of nucleosides as needed was non-inferior to
continuation of triple therapy (T) [1]. A pharmacoeco-
nomic analysis from the perspective of the Spanish
Healthcare System was performed to estimate cost-effec-
tiveness of both study arms.
Methods
OK04 methodology, baseline characteristics, and 96-week
efficacy/safety related outcomes showing non-inferiority
have been described elsewhere [1]. Briefly, 198 patients
were randomised 1:1 to the MT (n = 100) or T (n = 98).
Virological efficacy was defined as absence of virological
failure, i.e. two consecutive plasma HIV-RNA concentra-
tions >500 copies/mL through 96 weeks from the start of
the study without changes on randomized treatment.
Therapeutic efficacy included the maintenance of unde-
tectable viral load (<50 cop/mL) with the re-induction of
nucleosides in MT arm (if necessary). Data on resource
utilization related with follow-up, reported adverse events
(AE) management, concomitant medications and extra-
procedures were collected. Direct costs were computed
from resource utilization in Spanish 2007 euros. Incre-
mental cost-effectiveness ratio of MT vs. T (MT-T) was cal-
culated. An annual 3% discount rate was applied both for
costs and results. Sensitivity analyses were performed,
including a Montecarlo simulation of 10,000 samples.
Summary of results
After 96 weeks, therapeutic efficacy was 84.5% (MT) vs.
76.8% (T) (MT-T = 7.6%). MT showed better results vs. T
in time on therapeutic efficacy (incremental time mean,
3.7 weeks-patient), time on virological efficacy (incre-
mental time mean, 2.3 weeks-patient), and the propor-
tion of AEs related with study drug drop-outs (differential
%, -8.0%). No difference was found on number of future
treatment options. Differential costs were -5,563 €/
patient, mainly due to antiretroviral-related differential
drug acquistion costs. Economic analysis showed MT
dominance in cost/therapeutic efficacy, cost/patient-week
on therapeutic and virological efficacy, and cost/avoided
drop-out related to the study drug. Probabilistic sensitivity
analysis showed 93.65% scenarios where MT therapeutic
efficacy was cost effective (77.5% dominant).
Conclusion
LPV/r MT (including re-introduction of nucleosides as
needed) is an efficient option for maintenance therapy in
HIV-infected patients when compared with LPV/r T. This
may become a breakthrough treatment decision criterion
in current health saving costs environment.
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